Spanish bioscience R&D, features coronary DES and 26 Dx techs:
This article was originally published in Clinica
A drug-eluting coronary stent features in a survey of leading bioscientific R&D projects currently underway in Spain. According to the national bio-enterprise association ASEBIO, which performed the survey, the stent being developed by Barcelona-based Palau Pharma - one of 19 biotechnology companies engaged in pharmaceutical R&D - is now at phase III trial stage. A total of 119 human healthcare R&D projects are reported in the survey, of which 26 relate specifically to diagnostic/prognostic technologies. The leading clinical areas for diagnostic and medtech-related research, according to ASEBIO, are: oncology (32%), infectious diseases (22%) and cardiovascular disease (14%). The study will serve to inform the fourth bi-annual BioSpain international bioscience convention, which takes place during September 17-18 2008, in Granada.